SG11201807437XA - Antibodies specific to human poliovirus receptor (pvr) - Google Patents
Antibodies specific to human poliovirus receptor (pvr)Info
- Publication number
- SG11201807437XA SG11201807437XA SG11201807437XA SG11201807437XA SG11201807437XA SG 11201807437X A SG11201807437X A SG 11201807437XA SG 11201807437X A SG11201807437X A SG 11201807437XA SG 11201807437X A SG11201807437X A SG 11201807437XA SG 11201807437X A SG11201807437X A SG 11201807437XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pvr
- pct
- rule
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111010111111111110111011101111101111011111 International Bureau 0.. .... .. ...... ... (10) International Publication Number (43) International Publication Date WO 2017/149538 Al 8 September 2017 (08.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/1L2017/050256 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 28 February 2017 (28.02.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/301,727 1 March 2016 (01.03.2016) US 62/364,924 21 July 2016 (21.07.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: YISSUM RESEARCH DEVELOPMENT GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, COMPANY OF THE HEBREW UNIVERSITY OF TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, JERUSALEM LTD. [IL/IL]; Hi Tech Park, Edmond J. TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Safra Campus, Givat Ram P.O. Box 39135, 91390 Jerus- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, alem (IL). UNIVERSITY OF RIJEKA FACULTY OF LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, MEDICINE [HR/HR]; B. Branchetta 20, 51000 Rijeka, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Croatia (HR). GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventors: MANDELBOIM Ofer; 58 Hayarden St., Declarations under Rule 4.17: 6080858 Shoham (IL). KAYNAN, Noa S.; Kibbutz — of inventorship (Rule 4.17(N)) Barkai, 3786000 Kibbutz Barkai (IL). TSUKERMAN, Pinchas; 7/15 Hatzionut St., 9674111 Jerusalem (IL). Published: JONJIC, Stipan; Pogled 20, Marcelji, 51216 Viskovo — with international search report (Art. 21(3)) (HR). — with sequence listing part of description (Rule 5.2(a)) = (74) Agents: HORNIK, Vered et al.; WEBB & CO., P.O. Box 2189, 7612101 Rehovot (IL). 1-1 GC M kf) C:r 7r 11 IN 11 © (54) Title: ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) ei O (57) : The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its bind- ing to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical composi- tions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662301727P | 2016-03-01 | 2016-03-01 | |
US201662364924P | 2016-07-21 | 2016-07-21 | |
PCT/IL2017/050256 WO2017149538A1 (en) | 2016-03-01 | 2017-02-28 | Antibodies specific to human poliovirus receptor (pvr) |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807437XA true SG11201807437XA (en) | 2018-09-27 |
Family
ID=58410405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807437XA SG11201807437XA (en) | 2016-03-01 | 2017-02-28 | Antibodies specific to human poliovirus receptor (pvr) |
Country Status (15)
Country | Link |
---|---|
US (3) | US10906987B2 (en) |
EP (2) | EP4043492A1 (en) |
JP (1) | JP6966176B2 (en) |
KR (1) | KR20180133399A (en) |
CN (1) | CN109071666B (en) |
AU (2) | AU2017228055B2 (en) |
BR (1) | BR112018067522A2 (en) |
CA (1) | CA3015619A1 (en) |
CO (1) | CO2018010538A2 (en) |
ES (1) | ES2903280T3 (en) |
IL (2) | IL261200B2 (en) |
MX (2) | MX2018010445A (en) |
RU (1) | RU2756275C2 (en) |
SG (1) | SG11201807437XA (en) |
WO (1) | WO2017149538A1 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11098130B1 (en) | 2015-08-03 | 2021-08-24 | Tasrif Pharmaceutical, LLC | Antibodies and antibody fragments against the CD155 receptor and methods of use thereof |
ES2903280T3 (en) | 2016-03-01 | 2022-03-31 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Human Poliovirus (HRP) Receptor-Specific Antibodies |
WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
WO2019102456A1 (en) | 2017-11-27 | 2019-05-31 | University Of Rijeka Faculty Of Medicine | Immunotoxins for treating cancer |
EP3790900A1 (en) | 2018-05-09 | 2021-03-17 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human nectin4 |
MA53434A (en) | 2018-08-23 | 2021-12-01 | Seagen Inc | ANTI-TIGIT ANTIBODIES |
US11730762B2 (en) | 2018-08-30 | 2023-08-22 | HCW Biologics, Inc. | Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide |
CN112996805A (en) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | Multi-chain chimeric polypeptides and uses thereof |
CN113365663A (en) | 2018-08-30 | 2021-09-07 | Hcw生物科技公司 | Single-chain chimeric polypeptides and uses thereof |
AU2020207664A1 (en) * | 2019-01-13 | 2021-07-22 | University Of Rijeka Faculty Of Medicine | Antibodies specific to human Nectin-2 |
CN114269903A (en) | 2019-06-21 | 2022-04-01 | Hcw生物科技公司 | Multi-chain chimeric polypeptides and uses thereof |
US20220372161A1 (en) | 2019-10-08 | 2022-11-24 | Nectin Therapeutics Ltd. | Antibodies against the poliovirus receptor (pvr) and uses thereof |
KR102370915B1 (en) | 2019-10-22 | 2022-03-08 | 단국대학교 천안캠퍼스 산학협력단 | Primer set for loop-mediated isothermal amplification reaction for detecting Human Poliovirus, and use thereof |
IL295084A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Chromatography resin and uses thereof |
IL295077A (en) | 2020-02-11 | 2022-09-01 | Hcw Biologics Inc | Methods of treating age-related and inflammatory diseases |
CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
EP4143231A1 (en) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
IL298608A (en) | 2020-06-01 | 2023-01-01 | Hcw Biologics Inc | Methods of treating aging-related disorders |
CN112538108B (en) * | 2020-12-24 | 2022-06-28 | 郑州大学 | High affinity PVR mutants |
CA3229327A1 (en) * | 2021-08-20 | 2023-02-23 | Aftab S. Karim | Antibodies and antigen binding fragments against cd155 methods of use thereof |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2024047654A1 (en) | 2022-09-04 | 2024-03-07 | Nectin Therapeutics Ltd. | Drug conjugates of humanized anti pvr antibodies |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
DE69233528T2 (en) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Process for the preparation of multivalent antigen-binding proteins |
CA2128511C (en) | 1992-01-23 | 2006-11-07 | Andreas Pluckthun | Monomeric and dimeric antibody-fragment fusion proteins |
AU687010B2 (en) | 1992-07-17 | 1998-02-19 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
WO1995003832A1 (en) | 1993-07-30 | 1995-02-09 | Thomas Jefferson University | Intracellular immunization |
US6294353B1 (en) | 1994-10-20 | 2001-09-25 | Morphosys Ag | Targeted hetero-association of recombinant proteins to multi-functional complexes |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP0827544B1 (en) | 1995-05-23 | 2004-08-18 | MorphoSys AG | Multimeric proteins |
US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
US6264940B1 (en) * | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
US6518033B1 (en) | 1998-08-05 | 2003-02-11 | The Research Foundation Of State University Of New York | Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment |
US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
EP1392360B1 (en) | 2001-06-01 | 2011-11-30 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
EP1481993A1 (en) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
EP3214095B1 (en) | 2005-05-12 | 2019-12-11 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
WO2007016285A2 (en) | 2005-07-28 | 2007-02-08 | Novartis Ag | M-csf specific monoclonal antibody and uses thereof |
SG170749A1 (en) | 2005-12-20 | 2011-05-30 | Sbi Biotech Co Ltd | Anti-ilt7 antibody |
AR059922A1 (en) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS |
FR2909092B1 (en) * | 2006-11-24 | 2012-10-19 | Pf Medicament | NEW ANTI-PROLIFERATION ANTIBODIES |
EP2664346A1 (en) | 2007-03-20 | 2013-11-20 | Eli Lilly And Co. | Anti-sclerostin antibodies |
KR101855381B1 (en) | 2008-04-09 | 2018-05-09 | 제넨테크, 인크. | Novel compositions and methods for the treatment of immune related diseases |
JP5686361B2 (en) * | 2010-01-28 | 2015-03-18 | 国立大学法人 筑波大学 | Method for detecting cancer using soluble CD155 protein |
BR112013014321A2 (en) | 2010-12-08 | 2019-09-24 | Stem Centrx Inc | innovative modulators and methods of use |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
CN106167526A (en) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | RSPO bonding agent and its application |
JP5978314B2 (en) | 2011-12-27 | 2016-08-24 | エルジー・ケム・リミテッド | Lithium secondary battery and manufacturing method thereof |
MX2014014951A (en) | 2012-06-06 | 2015-03-13 | Oncomed Pharm Inc | Binding agents that modulate the hippo pathway and uses thereof. |
RU2015123032A (en) | 2012-12-04 | 2017-01-11 | Онкомед Фармасьютикалс, Инк. | IMMUNOTHERAPY WITH APPLICATION OF BINDING AGENTS |
MX2015010682A (en) | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Novel antibody conjugates and uses thereof. |
KR20220042248A (en) | 2013-07-16 | 2022-04-04 | 제넨테크, 인크. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
MX2016002545A (en) | 2013-08-28 | 2016-06-17 | Stemcentrx Inc | Engineered anti-dll3 conjugates and methods of use. |
US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
EP3119211A1 (en) | 2014-03-18 | 2017-01-25 | Gokmen, Vural | A solution for extending shelf life of ready-to-eat fresh fruits and/or vegetables and an application method thereof |
JO3620B1 (en) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers |
ES2903280T3 (en) | 2016-03-01 | 2022-03-31 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Human Poliovirus (HRP) Receptor-Specific Antibodies |
-
2017
- 2017-02-28 ES ES17713469T patent/ES2903280T3/en active Active
- 2017-02-28 MX MX2018010445A patent/MX2018010445A/en unknown
- 2017-02-28 CN CN201780027236.6A patent/CN109071666B/en active Active
- 2017-02-28 CA CA3015619A patent/CA3015619A1/en active Pending
- 2017-02-28 JP JP2018544355A patent/JP6966176B2/en active Active
- 2017-02-28 AU AU2017228055A patent/AU2017228055B2/en active Active
- 2017-02-28 KR KR1020187028157A patent/KR20180133399A/en active Search and Examination
- 2017-02-28 BR BR112018067522A patent/BR112018067522A2/en unknown
- 2017-02-28 RU RU2018134065A patent/RU2756275C2/en active
- 2017-02-28 IL IL261200A patent/IL261200B2/en unknown
- 2017-02-28 US US16/081,667 patent/US10906987B2/en active Active
- 2017-02-28 WO PCT/IL2017/050256 patent/WO2017149538A1/en active Application Filing
- 2017-02-28 EP EP21200696.9A patent/EP4043492A1/en active Pending
- 2017-02-28 SG SG11201807437XA patent/SG11201807437XA/en unknown
- 2017-02-28 EP EP17713469.9A patent/EP3423495B1/en active Active
- 2017-02-28 IL IL296874A patent/IL296874A/en unknown
-
2018
- 2018-08-29 MX MX2022014867A patent/MX2022014867A/en unknown
- 2018-10-01 CO CONC2018/0010538A patent/CO2018010538A2/en unknown
-
2020
- 2020-12-10 US US17/118,062 patent/US20210115150A1/en not_active Abandoned
-
2023
- 2023-08-15 US US18/450,022 patent/US20240018257A1/en active Pending
-
2024
- 2024-03-25 AU AU2024201912A patent/AU2024201912A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210115150A1 (en) | 2021-04-22 |
JP2019511212A (en) | 2019-04-25 |
WO2017149538A1 (en) | 2017-09-08 |
EP3423495A1 (en) | 2019-01-09 |
CA3015619A1 (en) | 2017-09-08 |
IL261200A (en) | 2018-10-31 |
CO2018010538A2 (en) | 2018-12-14 |
AU2024201912A1 (en) | 2024-04-11 |
KR20180133399A (en) | 2018-12-14 |
RU2018134065A3 (en) | 2020-07-20 |
US20240018257A1 (en) | 2024-01-18 |
EP4043492A1 (en) | 2022-08-17 |
JP6966176B2 (en) | 2021-11-10 |
AU2017228055B2 (en) | 2024-04-04 |
IL296874A (en) | 2022-11-01 |
US10906987B2 (en) | 2021-02-02 |
BR112018067522A2 (en) | 2019-02-05 |
CN109071666B (en) | 2022-06-28 |
RU2018134065A (en) | 2020-04-01 |
AU2017228055A1 (en) | 2018-09-20 |
RU2756275C2 (en) | 2021-09-29 |
EP3423495B1 (en) | 2021-10-20 |
MX2018010445A (en) | 2019-10-17 |
ES2903280T3 (en) | 2022-03-31 |
IL261200B (en) | 2022-11-01 |
IL261200B2 (en) | 2023-03-01 |
US20200040092A1 (en) | 2020-02-06 |
CN109071666A (en) | 2018-12-21 |
MX2022014867A (en) | 2023-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201805870YA (en) | Bispecific t cell engaging antibody constructs | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201909656YA (en) | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |